Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459219
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-06-10
Brief Title:
Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects
Sponsor:
Sven Schneider MD
Organization:
Medical University of Vienna
Study Overview
Official Title:
Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AllergyAge
Brief Summary:
Nasal allergen study in patients aged 60 with or without current respiratory allergy
Detailed Description:
Allergic rhinoconjunctivitis AR represents a major health burden affecting an estimated 14 billion people globally It is characterized by inflammation of the nasal mucosa and conjunctiva in response to exposure to airborne allergens eg pollen dust mites Interestingly with advanced age prevalence of AR decreases suggesting that a subset of allergic patients is able to develop tolerance towards allergens resulting in absence of symptoms Understanding this mechanism governing natural tolerance development in the context of allergy is critical for the development of new therapeutic approaches and thus the aim of the proposed study To address this question we plan to conduct a nasal allergen challenge study in patients aged 60 who 1 are currently suffering from birch pollen allergy 2 have a history of birch pollen allergy but absence of symptoms for at least three seasons and 3 never suffered from birch pollen allergy After signing informed consent and fulfilling selection criteria 38 patients per group will be intranasally challenged with birch pollen extract outside of the birch pollen season October and followed closely for up to 10 weeks to assess clinical parameters cytokines allergen-specific Immunoglobulin Ig levels as well as inflammatory cell subsets under controlled pollen exposure In summary this study will yield important information on the mechanisms underlying natural tolerance development in respiratory allergy with advanced age
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None